Pekin Hardy Strauss’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$539K Sell
1,826
-4,186
-70% -$1.1M 0.05% 297
2026
Q2
$1.36M Sell
6,012
-145
-2% -$25.8K 0.12% 184
2026
Q1
$1.06M Sell
6,157
-2,807
-31% -$520K 0.11% 201
2025
Q4
$1.79M Sell
8,964
-27,096
-75% -$4.92M 0.17% 135
2025
Q3
$5.64M Sell
36,060
-2,331
-6% -$370K 0.57% 46
2025
Q2
$5.83M Buy
38,391
+14,996
+64% +$2M 0.66% 43
2025
Q1
$3.52M Buy
+23,395
New +$3.92M 0.43% 64

Other funds holding CRL

Pekin Hardy Strauss's CRL Position: Q3 2026 in Review

Pekin Hardy Strauss reduced its Charles River Laboratories (CRL) stake by 70% in Q3 2026, selling an estimated $1.1M and leaving 1,826 shares worth $539K. The position accounts for 0.05% of the portfolio, ranked #297.

Pekin Hardy Strauss first reported a position in CRL in Q1 2025 and has held it in 7 quarters since. The position peaked at $5.83M in Q2 2025. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Pekin Hardy Strauss held 1,826 shares of Charles River Laboratories worth $539K as of Q3 2026.
  • Pekin Hardy Strauss sold 4,186 Charles River Laboratories shares in Q3 2026, an estimated $1.1M.
  • Charles River Laboratories made up 0.05% of Pekin Hardy Strauss's portfolio in Q3 2026, its #297 holding.
  • Pekin Hardy Strauss first reported a position in Charles River Laboratories in Q1 2025 and has held it in 7 quarters since.
  • Pekin Hardy Strauss's Charles River Laboratories position peaked at $5.83M in Q2 2025.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Pekin Hardy Strauss's 13F filing for Q3 2026, filed 2 Nov 2026.